Medicare Part D, the prescription drug benefit for seniors, has undergone a major overhaul under the Inflation Reduction Act, bringing significant changes that take full effect in 2026. The most notable reform is the elimination of the infamous "donut hole" coverage gap and a new $2,100 annual cap on out-of-pocket drug costs.
Key Changes in 2026
- The coverage gap (donut hole) is completely eliminated, so beneficiaries pay a consistent share throughout the year.
- Out-of-pocket spending is capped at $2,100, after which Medicare covers all additional drug costs.
- Insulin costs are capped at $35 per month for Part D plans.
- Medicare has negotiated lower prices for ten high-cost drugs, reducing costs for enrollees.
The benefit now consists of three phases: a deductible phase (up to $505 in 2026), an initial coverage phase (25% coinsurance for most drugs), and the catastrophic phase (after $2,100 out-of-pocket, with zero cost-sharing).
Formulary Tiers and Costs Plans organize drugs into tiers based on cost. Generic drugs are typically Tier 1 (lowest copay), while brand-name and specialty drugs fall into higher tiers. Understanding your plan's formulary is crucial to managing costs.
Late Enrollment Penalty Beneficiaries who delay enrolling in Part D may face a permanent late enrollment penalty equal to 1% of the national base beneficiary premium ($36.78 in 2026) for each month they were eligible but uninsured.
"The Inflation Reduction Act has fundamentally transformed Medicare Part D, making prescription drugs more affordable for millions of seniors," the video explains.
These changes aim to reduce financial burden on older Americans. Beneficiaries should review their plans during open enrollment to ensure optimal coverage.